Please assess the completion status of the following clinical trial:

Trial Title: Sedation With Sevoflurane Versus Propofol in Patients With Acute Respiratory Distress Syndrome Caused by COVID19 Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or more.~* Diagnosis of Acute Respiratory Distress Syndrome caused by COVID19 infection.~* Signature of Patient's Consent or Verbal Consent of Legal Representative~Exclusion Criteria:~* Intracranial hypertension~* Hypersensitivity to the active ingredient (propofol or sevoflurane) or to any of the excipients~* Current volume \< 250ml~* History of malignant hyperthermia~* Liver failure~* Neutropenia (\<0.5x109)~* Pregnant or lactating women~* Have received chemotherapy in the last month since their inclusion in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- SEVOFLURANE Group (Type: EXPERIMENTAL): None
- PROPOFOL Group (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).